These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

86 related items for PubMed ID: 1339591

  • 1. [Dual inhibition of converting enzyme and neutral endopeptidase: a research new way in the field of hypertension].
    Fournie-Zaluski MC.
    C R Seances Soc Biol Fil; 1992; 186(6):612-25. PubMed ID: 1339591
    [Abstract] [Full Text] [Related]

  • 2. Optimal recognition of neutral endopeptidase and angiotensin-converting enzyme active sites by mercaptoacyldipeptides as a means to design potent dual inhibitors.
    Coric P, Turcaud S, Meudal H, Roques BP, Fournie-Zaluski MC.
    J Med Chem; 1996 Mar 15; 39(6):1210-9. PubMed ID: 8632427
    [Abstract] [Full Text] [Related]

  • 3. [New approach in the research of analgesics and antihypertensive agents].
    Roques BP.
    Ann Pharm Fr; 1991 Mar 15; 49(6):317-26. PubMed ID: 1842170
    [Abstract] [Full Text] [Related]

  • 4. Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats.
    Gonzalez Vera W, Fournié-Zaluski MC, Pham I, Laboulandine I, Roques BP, Michel JB.
    J Pharmacol Exp Ther; 1995 Jan 15; 272(1):343-51. PubMed ID: 7815350
    [Abstract] [Full Text] [Related]

  • 5. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure.
    Trippodo NC, Robl JA, Asaad MM, Bird JE, Panchal BC, Schaeffer TR, Fox M, Giancarli MR, Cheung HS.
    J Pharmacol Exp Ther; 1995 Nov 15; 275(2):745-52. PubMed ID: 7473162
    [Abstract] [Full Text] [Related]

  • 6. Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension.
    Pham I, Gonzalez W, el Amrani AI, Fournié-Zaluski MC, Philippe M, Laboulandine I, Roques BP, Michel JB.
    J Pharmacol Exp Ther; 1993 Jun 15; 265(3):1339-47. PubMed ID: 8389863
    [Abstract] [Full Text] [Related]

  • 7. New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hypertension.
    Fournié-Zaluski MC, Coric P, Turcaud S, Rousselet N, Gonzalez W, Barbe B, Pham I, Jullian N, Michel JB, Roques BP.
    J Med Chem; 1994 Apr 15; 37(8):1070-83. PubMed ID: 8164250
    [Abstract] [Full Text] [Related]

  • 8. Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action.
    Fournie-Zaluski MC, Coric P, Thery V, Gonzalez W, Meudal H, Turcaud S, Michel JB, Roques BP.
    J Med Chem; 1996 Jun 21; 39(13):2594-608. PubMed ID: 8691458
    [Abstract] [Full Text] [Related]

  • 9. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.
    Campbell DJ, Anastasopoulos F, Duncan AM, James GM, Kladis A, Briscoe TA.
    J Pharmacol Exp Ther; 1998 Nov 21; 287(2):567-77. PubMed ID: 9808682
    [Abstract] [Full Text] [Related]

  • 10. Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: a potential therapeutic approach in hypertension.
    Fournié-Zaluski MC, Gonzalez W, Turcaud S, Pham I, Roques BP, Michel JB.
    Proc Natl Acad Sci U S A; 1994 Apr 26; 91(9):4072-6. PubMed ID: 8171037
    [Abstract] [Full Text] [Related]

  • 11. Marked difference between angiotensin-converting enzyme and neutral endopeptidase inhibition in vivo by a dual inhibitor of both enzymes.
    Anastasopoulos F, Leung R, Kladis A, James GM, Briscoe TA, Gorski TP, Campbell DJ.
    J Pharmacol Exp Ther; 1998 Mar 26; 284(3):799-805. PubMed ID: 9495836
    [Abstract] [Full Text] [Related]

  • 12. Cell surface metallopeptidases involved in blood pressure regulation: structure, inhibition and clinical perspectives.
    Roques BP.
    Pathol Biol (Paris); 1998 Mar 26; 46(3):191-200. PubMed ID: 9769915
    [Abstract] [Full Text] [Related]

  • 13. Characterization of a dual inhibitor of angiotensin I-converting enzyme and neutral endopeptidase.
    French JF, Flynn GA, Giroux EL, Mehdi S, Anderson B, Beach DC, Koehl JR, Dage RC.
    J Pharmacol Exp Ther; 1994 Jan 26; 268(1):180-6. PubMed ID: 8301555
    [Abstract] [Full Text] [Related]

  • 14. Mercaptoacyl dipeptides as orally active dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
    Fink CA, Carlson JE, McTaggart PA, Qiao Y, Webb R, Chatelain R, Jeng AY, Trapani AJ.
    J Med Chem; 1996 Aug 02; 39(16):3158-68. PubMed ID: 8759637
    [Abstract] [Full Text] [Related]

  • 15. Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus.
    Tikkanen T, Tikkanen I, Rockell MD, Allen TJ, Johnston CI, Cooper ME, Burrell LM.
    Hypertension; 1998 Oct 02; 32(4):778-85. PubMed ID: 9774379
    [Abstract] [Full Text] [Related]

  • 16. The renal antifibrotic effects of angiotensin-converting enzyme inhibition involve bradykinin B2 receptor activation in angiotensin II-dependent hypertension.
    Seccia TM, Belloni AS, Guidolin D, Sticchi D, Nussdorfer GG, Pessina AC, Rossi GP.
    J Hypertens; 2006 Jul 02; 24(7):1419-27. PubMed ID: 16794493
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Antihypertensive and natriuretic effects of CGS 30440, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase 24.11.
    Chatelain RE, Ghai RD, Trapani AJ, Odorico LM, Dardik BN, De Lombaert S, Lappe RW, Fink CA.
    J Pharmacol Exp Ther; 1998 Mar 02; 284(3):974-82. PubMed ID: 9495857
    [Abstract] [Full Text] [Related]

  • 19. Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels.
    Duncan AM, James GM, Anastasopoulos F, Kladis A, Briscoe TA, Campbell DJ.
    J Pharmacol Exp Ther; 1999 Apr 02; 289(1):295-303. PubMed ID: 10087017
    [Abstract] [Full Text] [Related]

  • 20. The effect of acute angiotensin-converting enzyme and neutral endopeptidase 24.11 inhibition on plasma extravasation in the rat.
    Sulpizio AC, Pullen MA, Edwards RM, Brooks DP.
    J Pharmacol Exp Ther; 2004 Jun 02; 309(3):1141-7. PubMed ID: 14769834
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.